The African American girls wearing pageant sashes and varying shades of purple walked through the hallways of a local medical organization, questions forming as they looked around with curiosity.

New analysis of Gazyva® shows the drug significantly reduces disease activity in adults with systemic lupus erythematosus.

More than three-quarters of lupus patients taking obinutuzumab (Gazvya) had a significant improvement in their symptoms after a year on the drug, researchers reported March 6 in The New England ...

Phase 3 trial data show that obinutuzumab significantly reduces disease activity in very active extrarenal lupus.

A bilingual support group addressing the psychological and educational needs of patients with lupus and their families is a valuable resource to help them cope, according to a study at Hospital for ...

Phase III results put obinutuzumab in line for approval ...

The Pennsylvania Delaware Valley Region is on the lookout for new support groups, and we're eager to connect with you! If you're interested in launching a support group with LFA, reach out to Wendy ...